Hospital stocks are bracing for another leg down on Monday, October 19. The National Pharmaceutical Pricing Authority (NPPA) issued an order over the weekend capping trade margins at 30% of the Maximum Retail Price for 138 non-scheduled oncology drugs. This includes high-value molecules like Bevacizumab. The revised pricing structure kicks in on November 9, 2026, but the market is pricing in the pain immediately.
Brokerage firm Nuvama calculates the hit will be most acute for Max Healthcare, projecting a 4% impact on margins. For the broader sector, the pressure on Average Revenue Per Operating Bed (ARPOB) is estimated at 1% to 2%. The consensus among analysts spoken to by CNBC-TV18 is blunt: hospitals will have to absorb this squeeze. They don't expect pharma companies to pass on any of this cost reduction to the patient.
The stock charts already tell a grim story. Apollo Hospitals shares are down 11.5% over the last month. Max Healthcare, Fortis Healthcare, and Healthcare Global have been hammered harder, with declines of 20%, 18%, and 16% respectively in the same period. The market has been punishing the sector on fears of margin compression, and this NPPA order validates those fears.
Abdukader Puranwala of ICICI Securities offered a slightly different angle, noting that the 30% cap isn't new to the market and remains better than the feared 16% figure. However, BS Ajaikumar, Chairman of Healthcare Global, warned in an earlier interview that low margins are already driving pharma companies to stop manufacturing certain cancer drugs. With over 100 drugs already under DPCO caps, supply issues could compound the financial hit.
The next catalyst is scheduled for October 27, when the Supreme Court hears the matter. Until then, the sector faces a binary risk environment. Hospitals may attempt to offset the oncology margin loss with price hikes in other segments, but the immediate sentiment is negative. Traders should watch for volume spikes in the AM open as the market digests the Nuvama and ICICI Securities notes.